Rahul Potluri

Last updated

Rahul Potluri
Rahul Potluri.jpg
Rahul Potluri
Born (1983-12-19) 19 December 1983 (age 40)
Vijayawada, Andhra Pradesh, India
NationalityBritish
Education Aston Medical School, Aston University, University of Manchester, University of Birmingham
Occupation(s)Doctor, scientific researcher
OrganizationsACALM (Algorithm for Comorbidities, Associations, Length of stay and Mortality) Study Unit

Rahul Potluri (born 19 December 1983) is a British physician, researcher and founder of ACALM (Algorithm for Comorbidites, Associations, Length of stay and Mortality) Study Unit, United Kingdom (UK). His clinical epidemiology research unit is one of the first to use big data in healthcare and medical research. His work has shown for the first time a link between high cholesterol and breast cancer. Further research has suggested the role of cholesterol and possibly statins improving the mortality in patients with breast cancer, lung cancer, prostate cancer and bowel cancer. Other prominent studies include health services research evaluating differences in death rates from weekend admission and discharge from UK hospitals, ethnic variations and the interplay between cardiovascular disease and mental health.

Contents

Early life and education

Rahul Potluri was born in India and moved to the UK at the age of eight.[ citation needed ] He attended King Edwards VI Five Ways School in Birmingham. He undertook medical undergraduate training at the University of Birmingham. His clinical training included medicine and cardiology in London and Manchester.[ citation needed ] He was appointed as Honorary Clinical Lecturer in Cardiology at Aston University, Birmingham, UK in 2013. [1] [2]

ACALM (Algorithm for Comorbidities, Associations, Length of stay and Mortality)

Potluri developed the ACALM methodology as a medical student and along with Hardeep Uppal founded the ACALM Study Unit in 2013. [1] Research from this unit is performed from a large clinical dataset of over one million patients which is developed using ACALM methodology from anonymous routinely collected data. [2]

Potluri is an expert in big data analytics in medical and healthcare research. He spoke on the topic at the European Society of Cardiology Conference in Rome, Italy, in August 2016 and highlighted potential developments in the field to come. [3]

Research

Cholesterol and Cancer

Potluri and the ACALM Study Unit showed for the first time in humans, a possible association between high cholesterol and breast cancer. This work was presented at the European Society of Cardiology, Frontiers in Cardiovascular Biology Conference in Barcelona, July 2014 and was widely reported in the global media. [2] [4] [5] [6] [7] [8] [9] Further research presented in 2016 showed the role of high cholesterol and possibly the role of statins improving the mortality and survival of patients with breast cancer, lung cancer, bowel cancer and prostate cancer and strengthening calls for a clinical trial of statins in cancer. [9] [10] [11]

Weekend effect on hospital care

Potluri presented research from the ACALM Study Unit at the European Society of Cardiology Conference in London, August 2015, which showed that heart attack patients admitted at the weekend died earlier compared to those admitted during the working week. [12] [13] Subsequent research looking at patients discharged from UK hospitals at the weekend had significantly worsened mortality and survival compared to those discharged during the working week. [14] [15] This was the first study of its kind from the UK. The significance and implications of these findings for UK are being widely debated. [15] [16] Further studies performed in 2016 and presented at the British Cardiovascular Society Conference showed that patients admitted with a diagnosis of atrial fibrillation during the weekend had worse mortality and patients with heart failure discharged at the weekend also had a higher risk of death. [17] [18]

Ethnic variations in healthcare

Research led by Potluri evaluating ethnic group variations in healthcare and particularly length of stay in hospital and mortality has been widely published. His work from the ACALM Study Unit showed that patients of South Asian origin stay in hospital for a shorter period of time compared to other ethnic groups in a variety of conditions such as Myocardial Infarction, Pulmonary Embolism, Stroke, Diabetes Mellitus and Atrial Fibrillation. [19] [20] [21] [22] Other research focusing on young South Asians has shown that they have a higher risk of Diabetes and associated heart disease compared to other ethnic groups. [21] [22] In 2010, he presented research at the World Congress of Cardiology in Beijing which showed that Haemorrhagic Stroke is increasing amongst South Asians and was reported in the media.[ citation needed ]

Cardiovascular disease and mental health

Potluri's research from 2007 has highlighted and shown the significant effect of mental health conditions on physical health and in particular cardiovascular disease. [23] [24] [25] A series of publications have led to raised awareness of psychiatric conditions amongst cardiovascular disease in the UK. Specifically research showing for the first time that mental health conditions prolong length of hospital stay in patients with heart failure highlighted significant cost and service provision implications for the United Kingdom National Health Service. [23]

Another important study which was widely reported showed that married people with heart attacks had significantly improved mortality and long-term survival compared to single and divorced patients. [26] [27] The implications of these findings were widely debated as Marriage was thought to be a proxy for psychosocial support which is essential for heart attack patient to ensure they take all the prescribed medications which determines long term outcome. [28] [29] [30]

Awards and prizes

He was awarded the Cochrane prize from the Faculty of Public Health, United Kingdom for his research on patients of South Asian origin in 2007. [31] Other international prizes include the Young Investigator Award from the International Atherosclerosis Society at the World Congress of Cardiology, Beijing in 2010, the Asian Society of Cardiovascular Imaging (ASCI) Travelling Fellowship from the Hong Kong College of Radiologists in 2011 and the Young Investigator Grant from the European Neurological Society, Milan in 2009. National prizes as a medical student have included the Wellcome Trust Prize in 2007, the Diabetes UK award in 2007 and the Denis Burkitt Award from the British Nutrition Foundation. [1]

See also

Related Research Articles

<span class="mw-page-title-main">Coronary artery disease</span> Reduction of blood flow to the heart

Coronary artery disease (CAD), also called coronary heart disease (CHD), or ischemic heart disease (IHD), is a type of heart disease involving the reduction of blood flow to the cardiac muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. CAD can cause stable angina, unstable angina, myocardial ischemia, and myocardial infarction.

<span class="mw-page-title-main">Cholesterol</span> Sterol biosynthesized by all animal cells

Cholesterol is the principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.

<span class="mw-page-title-main">Low-density lipoprotein</span> One of the five major groups of lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water. These groups, from least dense to most dense, are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL delivers fat molecules to cells. LDL has been associated with the progression of atherosclerosis.

<span class="mw-page-title-main">Statin</span> Class of drugs to lower cholesterol

Statins are a class of medications that reduce illness and mortality in people who are at high risk of cardiovascular disease.

<span class="mw-page-title-main">Scandinavian Simvastatin Survival Study</span>

The Scandinavian Simvastatin Survival Study, was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina. The study was sponsored by the pharmaceutical company Merck and enrolled 4,444 people from 94 centres in Scandinavia.

A saturated fat is a type of fat in which the fatty acid chains have all single bonds between the carbon atoms. A fat known as a glyceride is made of two kinds of smaller molecules: a short glycerol backbone and fatty acids that each contain a long linear or branched chain of carbon (C) atoms. Along the chain, some carbon atoms are linked by single bonds (-C-C-) and others are linked by double bonds (-C=C-). A double bond along the carbon chain can react with a pair of hydrogen atoms to change into a single -C-C- bond, with each H atom now bonded to one of the two C atoms. Glyceride fats without any carbon chain double bonds are called saturated because they are "saturated with" hydrogen atoms, having no double bonds available to react with more hydrogen.

<span class="mw-page-title-main">Cardiovascular disease</span> Class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

<span class="mw-page-title-main">Hypercholesterolemia</span> High levels of cholesterol in the blood

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, hyperlipoproteinemia, and dyslipidemia.

<span class="mw-page-title-main">Heart Protection Study</span>

The Heart Protection Study was a randomized controlled trial run by the Clinical Trial Service Unit, and funded by the Medical Research Council (MRC) and the British Heart Foundation (BHF) in the United Kingdom. It studied the use of the cholesterol lowering drug, simvastatin 40 mg and vitamin supplementation in people who were at risk of cardiovascular disease. It was led by Jane Armitage, an epidemiologist at the Clinical Trial Service Unit.

<span class="mw-page-title-main">Atorvastatin</span> Cholesterol-lowering medication

Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Simvastatin</span> Lipid-lowering medication

Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. It is also used to decrease the risk of heart problems in those at high risk. It is taken by mouth.

<span class="mw-page-title-main">Ezetimibe</span> Medication used to treat high cholesterol

Ezetimibe, sold under the brand name Zetia among others, is a medication used to treat high blood cholesterol and certain other lipid abnormalities. Generally it is used together with dietary changes and a statin. Alone, it is less preferred than a statin. It is taken by mouth. It is also available in the fixed-dose combinations ezetimibe/simvastatin, ezetimibe/atorvastatin, ezetimibe/rosuvastatin, and ezetimibe/bempedoic acid.

<span class="mw-page-title-main">Torcetrapib</span> Chemical compound

Torcetrapib was a drug being developed to treat hypercholesterolemia and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.

<span class="mw-page-title-main">Paul Ridker</span> American epidemiologist and academic

Paul M. Ridker is a cardiovascular epidemiologist and biomedical researcher. He is currently the Eugene Braunwald Professor of Medicine at Harvard University and Brigham and Women's Hospital, where he directs the Center for Cardiovascular Disease Prevention. Ridker also holds an appointment as Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

The lipid hypothesis is a medical theory postulating a link between blood cholesterol levels and the occurrence of cardiovascular disease. A summary from 1976 described it as: "measures used to lower the plasma lipids in patients with hyperlipidemia will lead to reductions in new events of coronary heart disease". It states, more concisely, that "decreasing blood cholesterol [...] significantly reduces coronary heart disease".

<span class="mw-page-title-main">Myocardial infarction</span> Interruption of cardiac blood supply

A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn.

The JUPITER trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels.

Aston Medical School (AMS) is part of Aston University, located in the city centre of Birmingham, in the United Kingdom. It is the 34th medical school in the UK and 6th in the Midlands. It exists to train doctors and to promote medical research. Aston Medical School was conceived and led by the founder Professor Asif Ahmed, who was the inaugural Executive Dean and also served as the first Pro-Vice-Chancellor for Health. The current Dean of Aston Medical School is Professor Anthony Hilton.

The West of Scotland Coronary Prevention Study was a landmark randomized controlled trial, published in 1995, that investigated the effects of pravastatin, a cholesterol-lowering drug, on primary prevention of coronary heart disease (CHD) in men with hypercholesterolemia. Conducted in the early 1990s, this study provided critical evidence on the benefits of statins in reducing cardiovascular events in individuals without a history of CHD. It concluded that statin treatment reduced CHD events by 31% after nearly five years of treatment.

References

  1. 1 2 3 Rahul Potluri Retrieved 28 September 2015.
  2. 1 2 3 Why Statins Could Be the Next Treatment for Breast Cancer. Retrieved 28 September 2015.
  3. ↑ Big Data in Cardiology: A Paradigm Shift? Retrieved 11 September 2016.
  4. ↑ Statins could help reduce women’s risk of breast cancer. Retrieved 28 September 2015.
  5. ↑ Association found between high cholesterol and breast cancer. Retrieved 28 September 2015.
  6. ↑ Study links hyperlipidaemia with breast cancer: Interview with Rahul Potluri. Retrieved 28 September 2015.
  7. ↑ High cholesterol could put women at risk of breast cancer, study suggests. Retrieved 28 September 2015.
  8. ↑ Statins could be used to cut risk of breast cancer. Retrieved 28 September 2015.
  9. 1 2 Cholesterol drugs could be used to fight breast cancer. Retrieved 28 September 2015.
  10. ↑ Cholesterol levels linked to breast cancer risk? Retrieved 28 September 2015.
  11. ↑ Statins linked to dramatically improved mortality rates for cancer patients.] Retrieved 11 September 2016.
  12. ↑ Heart attack victims more likely to die if admitted to hospital at weekend. Retrieved 28 September 2015.
  13. ↑ Weekends Are Not For Heart Attack Victims, Reveals Study. Retrieved 28 September 2015.
  14. ↑ Patients 'a third more likely' to die if discharged at the weekend. Retrieved 28 September 2015.
  15. 1 2 Hospital patients far more likely to die if sent home at weekend. Retrieved 28 September 2015.
  16. ↑ Hospital patients 'a third more likely' to die if discharged at the weekend. Retrieved 28 September 2015.
  17. ↑ Heart victims more at risk of dying if admitted to hospitals at weekend. Retrieved 11 September 2016.
  18. ↑ Two U.K studies validate weekend effect among heart patients. Retrieved 11 September 2016.
  19. ↑ Length of hospital stay is shorter in South Asian patients with ischaemic stroke. Retrieved 28 September 2015.
  20. ↑ Length of hospital stay is shorter in South Asian patients with acute pulmonary embolism. Retrieved 28 September 2015.
  21. 1 2 Young South Asian people at higher risk of diabetes and associated heart disease. Retrieved 28 September 2015.
  22. 1 2 A heavy-weight burden for healthcare. Retrieved 28 September 2015.
  23. 1 2 Research links mental health and heart failure recovery. Retrieved 11 September 2016.
  24. ↑ The burden and trends of psychiatric co-morbidities amongst patients with cardiomyopathy. Retrieved 28 September 2015.
  25. ↑ Potluri, R; Natalwala, A; Uppal, H; Heun, R (2008). "Cardiovascular risk factors in vascular dementia and ischaemic stroke". Neuroepidemiology. 31 (1): 67, discussion 68. doi: 10.1159/000140097 . PMID   18560245.
  26. ↑ Marriage may improve chances of surviving a heart attack say researchers. Retrieved 11 September 2016.
  27. ↑ Being married may improve your odds surviving heart attack. Retrieved 11 September 2016.
  28. ↑ Married people have greater chances of surviving a heart attack. Retrieved 11 September 2016.
  29. ↑ Scientists say marriage can improve your chances of surviving a heart attack. Retrieved 11 September 2016.
  30. ↑ Married People Have Higher Chance to Survive a Heart Attack Than Singles and Divorced. Retrieved 11 September 2016.
  31. ↑ UK: Faculty of Public Health: Prizes. Retrieved 28 September 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.